Company Also to Host Drug-Eluting Stent Symposium and Analyst Webcast
MENLO PARK, Calif., Oct. 16 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT) today announced that 2-year data from the CUSTOM I trial and 1-year data from the CUSTOM II trial of the company's investigational Custom NX(R) drug-eluting stent (DES) system will be presented at the Cardiovascular Research Foundation's (CRF) nineteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C., which is taking place October 20 to 25.
In addition, the company will conduct a number of activities during the meeting including an analyst webcast and teleconference to review the CUSTOM I and CUSTOM II clinical data, an evening drug-eluting stent symposium, and an exhibition at booth 6097 on Level 2 of the Washington Convention Center.
Schedule of Events
Sunday, October 21
Event: The Drug-Eluting Stent Summit: The XTENT CUSTOM Biolimus-Eluting
Modular Stent Program (Focus on Multivessel and Diffuse Disease)
Pieter Stella, M.D., Director of Cardiology, University Medical Center,
Utrecht, Netherlands, will present a historical overview and current
perspective on the treatment of multivessel coronary disease and the
treatment of long lesions. An overview of the Custom NX(R) DES System with
respect to the treatment of multivessel and diffuse disease will be
discussed, along with the one-year follow-up results of the CUSTOM II
Time/Location: 3:16-3:26 p.m. EDT; Ballroom C, 3rd Floor, Washington
Event: Evening Symposium -- Delivering Safety to Today's Patients
Professor Eberhard Grube, M.D., Chief of Cardiology at the HELIOS Heart
Center in Siebgurg, Germany and principal investigator of the CUSTOM I and
II clinical trials, will review the results to date from Biolimus A9(R)
DES clinical trials and registries. Professor Grube will present two-year
results from the CUSTOM I clinical trial and one-year results from the
CUSTOM II clinical trial.
Bernard de Bruyne, M.D. Ph.D, Cardiovascular Center, OLV Hospital in
Aalst, Belgium, will provide an overview of the Custom NX technology in a
presentation titled "XTENT Custom NX DES Systems: A Novel Approach to the
Percutaneous Treatment of Coronary Artery Disease (CAD)."
Time/Location: 8:00-10:00 p.m. EDT; Renaissance Washington, D.C. Hotel,
Grand Ballroom, 999 Ninth Street NW
Monday, October 22
Event: Analyst Webcast and Teleconference on CUSTOM I and CUSTOM II Data
XTENT will host a webcast and teleconference call to review the CUSTOM I
and CUSTOM II data presented on Sunday. The teleconference and slide
presentation can be accessed via the investor relations section of the
company's website at http://investor.xtentinc.com/events.cfm or by calling
888-663-2258 (from the U.S.), 913-312-1277 (international). Please dial in
or access the website five to ten minutes prior to the beginning of the
call. The webcast will be archived on the website for a minimum of three
months, and can be accessed at the investor relations portion of the
company's website at http://investor.xtentinc.com
Time/Location: 7:00 a.m. EDT
XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device. Note: XTENT Custom NX DES Systems have not been approved for sale by any regulatory authority.
Information about XTENT is available at our website at http://www.xtentinc.com.
|SOURCE XTENT, Inc.|
Copyright©2007 PR Newswire.
All rights reserved